Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.
Recognise a possible amniotic-fluid embolism, resuscitate cardiorespiratory collapse and early coagulopathy, and investigate competing diagnoses without delaying support.
Amniotic-fluid embolism is a rare syndrome of sudden maternal cardiorespiratory compromise with possible severe coagulopathy. It often presents during labour, birth or the early postpartum period, but real clinical presentations do not always follow a complete sequence. The term can misleadingly suggest an ordinary obstructing clot: the syndrome involves a complex maternal response to fetal or amniotic components, with pulmonary vascular effects, myocardial dysfunction and activation of coagulation.
The diagnosis is made in the clinical context while excluding more readily identifiable causes such as thrombotic pulmonary embolism, haemorrhage, anaphylaxis, high neuraxial block, local anaesthetic toxicity, eclampsia or sepsis. Labelling collapse as AFE must not terminate that search. Immediate survival depends on oxygen delivery, circulatory support and haemostatic control, all of which can begin before diagnostic certainty is possible.
AFE is associated with exposure of the maternal circulation to amniotic or fetal material and a severe host response. The exact trigger and susceptibility remain incompletely understood.
Events commonly occur around labour or delivery, when maternal and fetoplacental interfaces change. Associated obstetric factors do not provide a reliable screening test or justify prediction in an individual woman.
Pulmonary vasoconstriction and vascular effects can abruptly raise right-heart afterload, impair output and cause hypoxia. This mechanism is broader than a simple large mechanical plug in a pulmonary artery.
Ventricular performance can deteriorate during the syndrome, including subsequent left-ventricular failure. Serial assessment matters because the haemodynamic state at presentation may not remain constant.
Activation and consumption of haemostatic factors can produce severe disseminated intravascular coagulation and bleeding. Fibrinogen may fall rapidly, requiring urgent attention alongside red-cell replacement.
A previously stable woman may develop breathlessness, hypoxia, agitation, hypotension, seizure or collapse with little warning. Ask the team for the exact sequence, including recent medicines, neuraxial procedures, membrane rupture and the timing of birth.
Persistent vaginal or operative bleeding, oozing from venepuncture sites and unexpectedly severe fibrinogen depletion are important clues. Coagulation failure can occur early and be disproportionate to the initially measured loss, so do not assume every abnormal result is simply dilution.
Early pulmonary hypertension and right-ventricular dysfunction may evolve into left-ventricular impairment. The haemodynamic problem can therefore change over time; an indiscriminate large fluid load risks worsening a failing circulation.
Before birth, acute loss of maternal oxygenation or perfusion can cause fetal bradycardia. Restoring maternal circulation is central to fetal rescue, while the obstetric team determines urgent birth and follows current arrest guidance if cardiac arrest occurs.
A pulmonary clot can cause sudden hypoxia, shock and right-heart strain. Clinical risk, imaging when safe and the overall presentation determine investigation and treatment, rather than the shared word embolism.
Recent antimicrobial or anaesthetic administration, bronchospasm, rash, ascending block or a toxicity pattern may identify another cause. Time-critical treatment must proceed while the exact diagnosis is evaluated.
These major obstetric emergencies can each cause collapse and sometimes coagulopathy or seizures. Examine bleeding, infection indicators, blood pressure and neurological context to direct parallel treatment.
Profound loss of oxygen delivery can lead to maternal arrest and neurological injury. Prompt effective resuscitation and appropriate post-arrest care offer the opportunity for recovery.
Coagulopathy can amplify bleeding from the placental bed or trauma and create large transfusion requirements. Haemostatic replacement and mechanical or surgical source control are complementary.
Survivors may require rehabilitation after cardiac, respiratory, renal or neurological injury. The abrupt life-threatening event and newborn uncertainty can also have lasting emotional effects requiring support.
Surveillance criteria improve comparison of cases but cannot capture every atypical clinical presentation. A woman who falls outside a strict research timing definition still requires assessment and resuscitation of the actual emergency.
Fetal squames or hair in pulmonary tissue appear in historical pathological definitions. This does not create a useful blood test for an acutely ill living woman, and a negative sample cannot safely exclude the syndrome.
Thrombolysis is a treatment decision for suspected thrombotic pulmonary embolism in appropriate circumstances, not an automatic response to AFE. Severe associated coagulopathy makes an uncritical assumption particularly hazardous.
Unproven drug combinations discussed in case reports should not displace established resuscitation, critical-care support or haemorrhage control. Therapeutic decisions should address the demonstrated physiological problem and be reviewed as the picture evolves.
Waiting for confirmatory laboratory testing delays treatment of a syndrome that lacks an established accurate premortem diagnostic test.
Treating right-ventricular dilatation alone as proof of thrombotic pulmonary embolism can lead to an inappropriate intervention.
Assuming a normal early haemoglobin excludes dangerous bleeding overlooks acute loss and early consumptive coagulopathy.
Continuing unrestricted crystalloid infusion despite ventricular failure can worsen oxygenation and haemodilution.
Your practice draft is saved in this browser.
Ten minutes after birth, a woman develops sudden hypoxia and severe hypotension, followed by diffuse bleeding from cannula sites and a rapidly falling fibrinogen. Resuscitation has begun. Which diagnostic statement is most accurate?
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 7 Sept 2026; clinical approval remains outstanding.
Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes
It is not an AFE-specific antidote and must accompany source control and replacement of clotting deficits. Use only the intravenous route, assess thrombotic contraindications and renal impairment, and prevent confusion with neuraxial medicines.
There is no single fixed AFE infusion dose. Continuous monitoring is required; distinguish titrated support in a woman with a pulse from the standard bolus regimen used during cardiac arrest.